Does Aimovig List High Blood Pressure as a Side Effect?
Aimovig (erenumab-aooe), a CGRP inhibitor for migraine prevention, does not commonly cause high blood pressure (hypertension) in clinical trials or post-marketing data. Hypertension appears in the prescribing information as an uncommon adverse reaction, reported in less than 1% of patients.[1] Most side effects involve injection-site reactions (up to 45%), constipation (around 3-7%), and muscle spasms (1-3%).[1][2]
What Do Clinical Trial Data Show on Blood Pressure?
In pivotal trials like STRIVE and RESPECT, blood pressure changes were minimal and not linked to Aimovig. Mean systolic blood pressure rose by 0.4 mmHg and diastolic by 0.1 mmHg versus placebo. No significant hypertension signals emerged, even in long-term extensions up to 5 years.[2][3] Real-world studies, including registries with over 10,000 patients, confirm this pattern—no elevated hypertension risk.[4]
Why Might Someone Experience High Blood Pressure on Aimovig?
CGRP blockers like Aimovig dilate blood vessels, which typically lowers blood pressure. Rare reports could stem from:
- Underlying conditions (e.g., migraines often coexist with hypertension).
- Concomitant meds or lifestyle factors.
- Hypersensitivity reactions (e.g., Raynaud's phenomenon in <1%, causing vasospasm).[1]
Patient forums note anecdotal blood pressure spikes, often tied to stress or unrelated issues, not confirmed causation.[5]
Who Should Monitor Blood Pressure Closely?
Those with pre-existing hypertension, cardiovascular disease, or on blood pressure meds. The label advises monitoring; discontinue if severe hypertension develops (rare cases reported).[1] No black-box warnings apply. Consult a doctor for personalized risk—baseline BP checks are standard before starting.
How Does Aimovig Compare to Other Migraine Preventives on BP Effects?
| Drug | BP Impact | Key Notes |
|------|-----------|-----------|
| Aimovig (erenumab) | Neutral/minimal rise | Lowest hypertension reports among CGRPs.[2] |
| Emgality (galcanezumab) | Similar neutral | Rare hypertension (<1%).[6] |
| Nurtec (rimegepant, acute) | Slight increase possible | Monitor in hypertensives.[7] |
| Beta-blockers (e.g., propranolol) | Lowers BP | First-line but causes fatigue.[8] |
| Topiramate | Neutral/slight drop | Weight loss may aid BP.[8] |
CGRP class overall shows favorable cardiovascular profile versus older options.[3]
[1]: Aimovig Prescribing Information (Amgen)
[2]: DrugPatentWatch.com - Aimovig Safety Profile
[3]: Goadsby et al., NEJM 2017 (STRIVE trial)
[4]: Ashina et al., Lancet Neurol 2021 (real-world data)
[5]: Patient reviews aggregated from Drugs.com
[6]: Emgality PI (Lilly)
[7]: Nurtec ODT PI (Pfizer)
[8]: AAN/AHS Migraine Guidelines 2021